Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000923177 | SCV001068641 | likely benign | not provided | 2018-12-18 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000923177 | SCV003815476 | uncertain significance | not provided | 2019-12-06 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000923177 | SCV005217136 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Department of Pathology and Laboratory Medicine, |
RCV000923177 | SCV001554264 | likely benign | not provided | no assertion criteria provided | clinical testing | The PIEZO2 p.A336T variant was not identified in the literature but was identified in dbSNP (ID: rs368601054) and ClinVar (classified as likely benign by Invitae). The variant was identified in control databases in 64 of 175860 chromosomes (1 homozygous) at a frequency of 0.0003639, and was observed at the highest frequency in the South Asian population in 53 of 22730 chromosomes (freq: 0.002332) (Genome Aggregation Database March 6, 2019, v2.1.1). The p.A336 residue is not conserved in mammals and computational analyses (MUT Assesor, PolyPhen-2, SIFT, MutationTaster, Revel, FATHMM, MetaLR, DANN) do not suggest a high likelihood of impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (Splice AI exome) do not predict a deleterious effect on splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. |